Shanhua Lin | Authors

Monoclonal antibody (mAb) treatment is among the most effective method of diagnosis and treatment of a broad range of diseases, including autoimmune disorders, cardiovascular diseases, infectious diseases, cancer, and inflammation. There is an extensive development pipeline for protein and mAb therapeutics, emphasizing the need for innovative and efficient analytical tools that result in faster analysis times. This article explores the use of supermacroporous particles for the analysis of mAbs.

The biopharmaceutical industry continues to focus on the development of biotherapeutic monoclonal antibody (mAbs) drugs. In this article, the compatibility of SEC coupled with HRAM–MS for the analysis of mAbs is demonstrated.